Literature DB >> 26561074

Herba Epimedii: An Ancient Chinese Herbal Medicine in the Prevention and Treatment of Osteoporosis.

Lili Wang, Yu Li, Yubo Guo, Rufeng Ma, Min Fu, Jianzhao Niu, Sihua Gao, Dongwei Zhang1.   

Abstract

Herba Epimedii (HEP) known as YinYangHuo in Chinese is the dried leaf of the Epimediium, and has been historically used in combination with other herbs to treat skeletal diseases in traditional Chinese medicine (TCM). Here, we review the historical TCM interpretation of the action of HEP, its use in clinical trials, its main phytochemical constituents and its pharmacological findings. 85 clinical trials were identified which used HEP in TCM prescriptions with other herbs to treat primary and secondary osteoporosis from 2005 to now. More than 60 individual compounds were isolated and characterized from HEP and studied in various animal and cell models. HEP and its constituents exhibited a variety of anti-resorptive and bone formation-stimulating effects, which target different pathways in the bone remodeling cycle. These compounds may provide new perspectives in alternative treatment regimes and reveal novel chemical scaffolds for the development of anti-osteoporotic drugs. These approaches are also useful for guiding our research to employ an integrative therapeutic approach to treat complex diseases such as osteoporosis diseases which could be superior to the conventional single target - single drug approach.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26561074     DOI: 10.2174/1381612822666151112145907

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  26 in total

1.  The flavonol glycoside icariin promotes bone formation in growing rats by activating the cAMP signaling pathway in primary cilia of osteoblasts.

Authors:  Wengui Shi; Yuhai Gao; Yuanyuan Wang; Jian Zhou; Zhenlong Wei; Xiaoni Ma; Huiping Ma; Cory J Xian; Jufang Wang; Keming Chen
Journal:  J Biol Chem       Date:  2017-10-31       Impact factor: 5.157

2.  Rehmanniae Radix Preparata suppresses bone loss and increases bone strength through interfering with canonical Wnt/β-catenin signaling pathway in OVX rats.

Authors:  C Liu; L Wang; R Zhu; H Liu; R Ma; B Chen; L Li; Y Guo; Q Jia; S Shi; D Zhao; F Mo; B Zhao; J Niu; M Fu; A N Orekhov; D Brömme; S Gao; D Zhang
Journal:  Osteoporos Int       Date:  2018-08-27       Impact factor: 4.507

3.  Psoralen stimulates osteoblast proliferation through the activation of nuclear factor-κB-mitogen-activated protein kinase signaling.

Authors:  Feimeng Li; Qihuo Li; Xiaoqing Huang; Yunting Wang; Chana Ge; Yong Qi; Wei Guo; Hongtao Sun
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

4.  Epimedium for Osteoporosis Based on Western and Eastern Medicine: An Updated Systematic Review and Meta-Analysis.

Authors:  Shihua Shi; Fei Wang; Yong Huang; Bonan Chen; Caixia Pei; Demei Huang; Xiaomin Wang; Yilan Wang; Shuo Kou; Weihao Li; Tianhong Ma; Yongcan Wu; Zhenxing Wang
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

Review 5.  The Anticancer Properties of Herba Epimedii and Its Main Bioactive Componentsicariin and Icariside II.

Authors:  Meixia Chen; Jinfeng Wu; Qingli Luo; Shuming Mo; Yubao Lyu; Ying Wei; Jingcheng Dong
Journal:  Nutrients       Date:  2016-09-13       Impact factor: 5.717

Review 6.  Effects of Chinese herbal formula Erxian decoction for treating osteoporosis: a systematic review.

Authors:  Jin-Yu Li; Yu-Song Jia; Li-Min Chai; Xiao-Hong Mu; Sheng Ma; Lin Xu; Xu Wei
Journal:  Clin Interv Aging       Date:  2017-01-04       Impact factor: 4.458

Review 7.  Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases.

Authors:  Lili Wang; Rufeng Ma; Chenyue Liu; Haixia Liu; Ruyuan Zhu; Shuzhen Guo; Minke Tang; Yu Li; Jianzhao Niu; Min Fu; Sihua Gao; Dongwei Zhang
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 8.  Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine.

Authors:  Xu Wei; Aili Xu; Hao Shen; Yanming Xie
Journal:  BMC Complement Altern Med       Date:  2017-02-13       Impact factor: 3.659

Review 9.  Diabetic Osteoporosis: A Review of Its Traditional Chinese Medicinal Use and Clinical and Preclinical Research.

Authors:  Rufeng Ma; Ruyuan Zhu; Lili Wang; Yubo Guo; Chenyue Liu; Haixia Liu; Fengwei Liu; Hongjun Li; Yu Li; Min Fu; Dongwei Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-09-06       Impact factor: 2.629

10.  Analysis of Molecular Mechanism of Erxian Decoction in Treating Osteoporosis Based on Formula Optimization Model.

Authors:  Lang Yang; Liuyi Fan; Kexin Wang; Yupeng Chen; Lan Liang; Xuemei Qin; Aiping Lu; Peng Cao; Bin Yu; Daogang Guan; Junxiang Peng
Journal:  Oxid Med Cell Longev       Date:  2021-06-18       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.